Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder
Status:
Recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
Overactive bladder is more prevalent among the Sjogren syndrome's population compare to the
general population. Both anti-muscarinic agent and beta-3 agonist are recommended as second
line treatment for overactive bladder syndrome. However, theoretically, undesirable effect of
the anti-muscarinic agent such as dry mouth and constipation would make it less suitable for
Sjogren syndrome patient with overactive bladder. Therefore, this study is a randomised
control study with the aim to evaluate the therapeutic effect of beta-3 agonist and
anti-muscarinic agent on overactive bladder among sjogren's syndrome patient.